Ken Mills is the President and Chief Executive Officer of REGENXBIO. He is a founder of the company, which was established in 2009 with a mission to improve lives through the curative potential of gene therapy. With its proprietary NAV® Technology Platform, REGENXBIO is developing best-in-class gene therapy treatments for patients facing a wide range of therapeutic needs. Mr. Mills led REGENXBIO’s initial public offering in 2015 and continues to grow the company into a leading gene therapy biotech, with end-to-end capabilities including research and development, clinical, and manufacturing. Today, REGENXBIO has 400 employees advancing a pipeline of adeno-associated virus (“AAV”) therapeutics through preclinical and clinical development.

Prior to co-founding REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills serves as a Board Member of the Universities at Shady Grove and the Montgomery County Economic Development Corporation. Mr. Mills received an S.B in chemistry from the Massachusetts Institute of Technology.